On June 18, 2025, Moleculin Biotech announced the FDA's approval of their Initial Pediatric Study Plan for testing Annamycin combined with Cytarabine in children with relapsed/refractory acute myeloid leukemia. The study is expected to start in late 2027 and includes children aged 6 months and older.